<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Silverback Therapeutics Inc — News on 6ix</title>
    <link>https://6ix.com/company/silverback-therapeutics-inc</link>
    <description>Latest news and press releases for Silverback Therapeutics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 15 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/silverback-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c32478dffbe2df119a16.webp</url>
      <title>Silverback Therapeutics Inc</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc</link>
    </image>
    <item>
      <title>neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/neffyr-epinephrine-nasal-spray-approved-in-canada-as-the-first-and-only-needle-free-emergency-treatment-of-allergic-reactions-anaphylaxis</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/neffyr-epinephrine-nasal-spray-approved-in-canada-as-the-first-and-only-needle-free-emergency-treatment-of-allergic-reactions-anaphylaxis</guid>
      <pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
      <description>neffy offers a new delivery method for epinephrine in Canada for adults and children (&gt;30 kg) living with severe allergic reactions ALK- Abelló A/S, which</description>
    </item>
    <item>
      <title>ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-receives-fda-approval-to-remove-age-requirement-from-neffyr-1-mg-epinephrine-nasal-spray-label</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-receives-fda-approval-to-remove-age-requirement-from-neffyr-1-mg-epinephrine-nasal-spray-label</guid>
      <pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
      <description>Children were previously required to weigh ≥33 lbs.</description>
    </item>
    <item>
      <title>ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-updates-on-neffyr-epinephrine-nasal-spray-commercialization</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-updates-on-neffyr-epinephrine-nasal-spray-commercialization</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026</description>
    </item>
    <item>
      <title>ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-fourth-quarter-and-full-year-2025-financial-results-and-participation-at-upcoming-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-fourth-quarter-and-full-year-2025-financial-results-and-participation-at-upcoming-conferences</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a</description>
    </item>
    <item>
      <title>ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-showcase-scientific-innovation-130000186</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-showcase-scientific-innovation-130000186</guid>
      <pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
      <description>-Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price -When factoring in patients’ dislike of needle-based administration, the value of a nasal option increased by more than 25% SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceut</description>
    </item>
    <item>
      <title>EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to &lt;30 kg</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/eurneffyr-1-mg-adrenaline-nasal-spray-recommended-approval-eu-emergency-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/eurneffyr-1-mg-adrenaline-nasal-spray-recommended-approval-eu-emergency-treatment</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who</description>
    </item>
    <item>
      <title>California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/california-k-12-schools-now-eligible-neffyinschools-program-offering-needle-free</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/california-k-12-schools-now-eligible-neffyinschools-program-offering-needle-free</guid>
      <pubDate>Wed, 21 Jan 2026 05:00:00 GMT</pubDate>
      <description>California joins 23 other states eligible to receive free neffy® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS</description>
    </item>
    <item>
      <title>neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/neffyr-epinephrine-nasal-spray-approved-china-first-and-only-community-use</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/neffyr-epinephrine-nasal-spray-approved-china-first-and-only-community-use</guid>
      <pubDate>Mon, 29 Dec 2025 05:00:00 GMT</pubDate>
      <description>neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (&gt;30 kg) living with severe allergic</description>
    </item>
    <item>
      <title>ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-participate-piper-sandler-37th-annual-healthcare-conference-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-participate-piper-sandler-37th-annual-healthcare-conference-2025</guid>
      <pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients</description>
    </item>
    <item>
      <title>ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights  for neffy® (epinephrine nasal spray)</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by</description>
    </item>
    <item>
      <title>ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharma-launches-get-neffyr-us-patients-severe-allergic-reactions-improve-access</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharma-launches-get-neffyr-us-patients-severe-allergic-reactions-improve-access</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is</description>
    </item>
    <item>
      <title>UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Scientific Meeting</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/update-ars-pharma-present-real-world-data-intranasal-epinephrine-2025-american</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/update-ars-pharma-present-real-world-data-intranasal-epinephrine-2025-american</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral</description>
    </item>
    <item>
      <title>ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-announces-conference-call-and-webcast-its-third-quarter-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-announces-conference-call-and-webcast-its-third-quarter-2025</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients</description>
    </item>
    <item>
      <title>ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Scientific Meeting</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharma-present-real-world-data-intranasal-epinephrine-2025-american-college</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharma-present-real-world-data-intranasal-epinephrine-2025-american-college</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral</description>
    </item>
    <item>
      <title>ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-receives-favorable-decision-european-patent-office-patent-related</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-receives-favorable-decision-european-patent-office-patent-related</guid>
      <pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
      <description>SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering</description>
    </item>
    <item>
      <title>ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-secures-250-million-loan-facility-ra-capital-management-and-omers</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/ars-pharmaceuticals-secures-250-million-loan-facility-ra-capital-management-and-omers</guid>
      <pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
      <description>Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq:</description>
    </item>
    <item>
      <title>neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/neffyr-epinephrine-nasal-spray-approved-japan-first-and-only-needle-free-emergency</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/neffyr-epinephrine-nasal-spray-approved-japan-first-and-only-needle-free-emergency</guid>
      <pubDate>Fri, 19 Sep 2025 04:00:00 GMT</pubDate>
      <description>neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (&gt;15 kg) living</description>
    </item>
    <item>
      <title>ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/adarx-pharmaceuticals-appoints-industry-veteran-laura-shawver-phd-as-board-chair</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/adarx-pharmaceuticals-appoints-industry-veteran-laura-shawver-phd-as-board-chair</guid>
      <pubDate>Wed, 17 Sep 2025 13:00:00 GMT</pubDate>
      <description>– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced the appointment of Laura Shawver, Ph.D., as Chair of its Board of Directors. “We are honored to welcome Dr. Shawver to our Board. Laura’s outstandi</description>
    </item>
    <item>
      <title>80% of Prior Authorizations Automated, 75% Fewer Denials: SPRY Unveils Prior Auth &amp; Eligibility Solution for Rehab Therapy Clinics</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/80percent-of-prior-authorizations-automated-75percent-fewer-denials-spry-unveils-prior-auth-and-eligibility-solution-for-rehab-therapy-clinics</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/80percent-of-prior-authorizations-automated-75percent-fewer-denials-spry-unveils-prior-auth-and-eligibility-solution-for-rehab-therapy-clinics</guid>
      <pubDate>Mon, 15 Sep 2025 13:03:00 GMT</pubDate>
      <description>SAN FRANCISCO, September 15, 2025--SPRY launches an AI-powered prior authorization &amp; eligibility solution for rehab clinics, cutting denials by 75% and preparing practices for CMS 2026.</description>
    </item>
    <item>
      <title>Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis</title>
      <link>https://6ix.com/company/silverback-therapeutics-inc/news/real-world-evidence-supports-clinical-effectiveness-neffyr-epinephrine-nasal-spray</link>
      <guid isPermaLink="true">https://6ix.com/company/silverback-therapeutics-inc/news/real-world-evidence-supports-clinical-effectiveness-neffyr-epinephrine-nasal-spray</guid>
      <pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
      <description>Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients</description>
    </item>
  </channel>
</rss>